MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - NATCO PHARMA
ASTRAZENECA PHARMA vs NATCO PHARMA - Comparison Results
Current Valuations
| ASTRAZENECA PHARMA | NATCO PHARMA | ASTRAZENECA PHARMA/ NATCO PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 90.9 | 13.6 | 667.7% | View Chart |
| P/BV | x | 20.0 | 2.8 | 704.9% | View Chart |
| Dividend Yield | % | 0.0 | 1.6 | - |
Financials
 ASTRAZENECA PHARMA  NATCO PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
NATCO PHARMA Mar-18 |
ASTRAZENECA PHARMA/ NATCO PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 1,080 | 118.3% | |
| Low | Rs | 883 | 671 | 131.5% | |
| Sales per share (Unadj.) | Rs | 228.4 | 592.1 | 38.6% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 188.4 | 5.5% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 206.3 | 7.9% | |
| Dividends per share (Unadj.) | Rs | 0 | 8.25 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.9 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 833.6 | 11.8% | |
| Shares outstanding (eoy) | m | 25.00 | 36.90 | 67.8% | |
| Bonus/Rights/Conversions | - | IS | - | ||
| Price / Sales ratio | x | 4.7 | 1.5 | 319.8% | |
| Avg P/E ratio | x | 104.2 | 4.6 | 2,242.7% | |
| P/CF ratio (eoy) | x | 66.4 | 4.2 | 1,565.6% | |
| Price / Book Value ratio | x | 10.9 | 1.1 | 1,041.2% | |
| Dividend payout | % | 0 | 4.4 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 32,311 | 83.6% | |
| No. of employees | `000 | 1.4 | 4.8 | 28.1% | |
| Total wages/salary | Rs m | 1,535 | 3,256 | 47.2% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 4,522.5 | 93.1% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 674.0 | 168.0% | |
| Avg. net profit/employee | Rs Th | 191.1 | 1,439.0 | 13.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 21,848 | 26.1% | |
| Other income | Rs m | 123 | 404 | 30.3% | |
| Total revenues | Rs m | 5,833 | 22,252 | 26.2% | |
| Gross profit | Rs m | 463 | 9,284 | 5.0% | |
| Depreciation | Rs m | 147 | 662 | 22.3% | |
| Interest | Rs m | 0 | 154 | 0.0% | |
| Profit before tax | Rs m | 438 | 8,872 | 4.9% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 179 | 1,920 | 9.3% | |
| Profit after tax | Rs m | 259 | 6,952 | 3.7% | |
| Gross profit margin | % | 8.1 | 42.5 | 19.1% | |
| Effective tax rate | % | 40.8 | 21.6 | 188.7% | |
| Net profit margin | % | 4.5 | 31.8 | 14.3% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 21,307 | 15.1% | |
| Current liabilities | Rs m | 2,070 | 5,920 | 35.0% | |
| Net working cap to sales | % | 20.0 | 70.4 | 28.3% | |
| Current ratio | x | 1.6 | 3.6 | 43.1% | |
| Inventory Days | Days | 72 | 73 | 98.8% | |
| Debtors Days | Days | 35 | 107 | 32.8% | |
| Net fixed assets | Rs m | 790 | 14,986 | 5.3% | |
| Share capital | Rs m | 50 | 369 | 13.6% | |
| "Free" reserves | Rs m | 2,419 | 30,353 | 8.0% | |
| Net worth | Rs m | 2,469 | 30,760 | 8.0% | |
| Long term debt | Rs m | 0 | 0 | - | |
| Total assets | Rs m | 4,605 | 37,151 | 12.4% | |
| Interest coverage | x | NM | 58.6 | - | |
| Debt to equity ratio | x | 0 | 0 | - | |
| Sales to assets ratio | x | 1.2 | 0.6 | 210.8% | |
| Return on assets | % | 5.6 | 19.1 | 29.4% | |
| Return on equity | % | 10.5 | 22.6 | 46.4% | |
| Return on capital | % | 17.7 | 29.3 | 60.4% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 300 | 10,322 | 2.9% | |
| Fx outflow | Rs m | 2,015 | 2,978 | 67.6% | |
| Net fx | Rs m | -1,715 | 7,343 | -23.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 4,636 | 1.9% | |
| From Investments | Rs m | -94 | -11,155 | 0.8% | |
| From Financial Activity | Rs m | NA | 6,509 | 0.0% | |
| Net Cashflow | Rs m | -6 | -18 | 31.7% | |
Share Holding
| Indian Promoters | % | 0.0 | 52.0 | - | |
| Foreign collaborators | % | 75.0 | 1.5 | 5,102.0% | |
| Indian inst/Mut Fund | % | 0.3 | 7.8 | 3.8% | |
| FIIs | % | 15.7 | 16.6 | 94.4% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 26.0 | 35.0% | |
| Shareholders | 12,856 | 25,395 | 50.6% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: WOCKHARDT J.B.CHEMICALS ORCHID PHARMA LTD BIOCON FULFORD INDIA
Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 160 Points Higher; IT and Healthcare Stocks Witness Buying(Closing)
Indian share markets traded on a positive note most of the day and ended higher. Gains were largely seen in the IT sector and healthcare sector, while capital goods stocks witnessed selling pressure.
Related Views on News
NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)
May 28, 2019 | Updated on May 28, 2019For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Mar 29, 2019 | Updated on Mar 29, 2019Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)
Feb 14, 2019 | Updated on Feb 14, 2019For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsMost Popular
I Believe this is the Best Stock to Buy Today(Profit Hunter)
Jul 3, 2019The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.
This Smallcap Stock could be the next Page Industries(Profit Hunter)
Jul 2, 2019The smallcap rebound is taking longer to play out...and that's good news as it gives you more of action time and opportunities to invest in.
The Indian Rating Agency Cleanup Has Begun and this Cheap Stock Could be the Best Bet(The 5 Minute Wrapup)
Jul 2, 2019The last time this big rating agency was as cheap and out-of-favour as it is today, the stock had corrected by 40% in six months.
2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)
Jul 12, 2019Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.
After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)
Jul 8, 2019A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...
More|
| |
ASTRAZENECA PHARMA SHARE PRICE
Jul 15, 2019 (Close)
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA - FDC LTD. COMPARISON
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.